No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Novaerus Expands Distribution Network in China

Editor: What To Know

  • Novaerus is a company that manufactures and sells patented medical-grade, clean air solutions, has partnered with seven established distributors across China, in regions such as Hubei, Beijing, Shanghai, Zhejiang, Guangzhou City and the Chinese special administrative regions of Hong Kong and Macau.
  • Novaerus portable air dis-infection units will be available to healthcare facilities in the regions of Hubei, Beijing, Shanghai, Zhejiang, Guangzhou City and the Chinese special administrative regions of Hong Kong and Macau.
  • The new partnerships are welcomed at a time of growing concern surrounding the recent infectious outbreak, caused by a novel coronavirus, that started in Wuhan, Hubei Province, China.

Novaerus is a company that manufactures and sells patented medical-grade, clean air solutions, has partnered with seven established distributors across China, in regions such as Hubei, Beijing, Shanghai, Zhejiang, Guangzhou City and the Chinese special administrative regions of Hong Kong and Macau.

The new partnerships are welcomed at a time of growing concern surrounding the recent infectious outbreak, caused by a novel coronavirus, that started in Wuhan, Hubei Province, China.

Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans.

Global health authorities are currently monitoring the recent outbreak, which has been spreading across China, with a growing number of additional cases identified globally.

Symptoms of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. According to the World Health Organization (WHO), in more severe cases, the infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. There are currently over 28,000 confirmed cases of the virus, with over 500 reported deaths.

It’s not yet clear how easily 2019-nCoV spreads from person-to-person. However, previous strains of coronavirus, MERS and SARS, were thought to have been spread via respiratory droplets produced when an infected person coughs or sneezes, similar to how influenza and other respiratory pathogens spread.

“The most difficult disease transmission route to guard against is airborne because we have very little to protect us when we breathe,” says Dr Kevin Devlin, CEO at WellAir, the parent company of Novaerus. “Infection prevention specialists have pointed out that surgical masks are not designed to keep out viruses. Cleaning the air is a fundamental component of managing infectious outbreaks.”

Due to the small size of viruses, many clean air solutions, including standalone filtration, are unable to trap viral particles. Novaerus portable air dis-infection units use a non-selective, rapid killing, patented plasma technology, offering a unique and safe solution to kill airborne viruses 24/7.  The technology has also been independently tested to reduce MS2 Bacteriophage, a commonly used surrogate for SARS-CoV* (Coronavirus) by 99.99%.

“Given the rapid and consistent kill rates achieved using Novaerus, it is reasonable to anticipate that our plasma technology will show similar impact and rapid kill rates across all viral particles,” says Dr Felipe Soberon, Chief Technology Officer at WellAir.

Novaerus portable air dis-infection units will be available to healthcare facilities in the regions of Hubei, Beijing, Shanghai, Zhejiang, Guangzhou City and the Chinese special administrative regions of Hong Kong and Macau.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy